Upcoming results from a bunch of clinical trials could extend the rally stocks have already been enjoying the past few years.
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 626.12% and ...
Market values of major tech firms declined in August amid concerns over escalating artificial intelligence infrastructure ...
International drugmaker, Eli Lilly, announced plans in May to invest $5.3 billion (€4.9 billion) in a new manufacturing site ...
Indianapolis-based Eli Lilly and Co. is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed ...
In August, most of the $347 million went to biotechnology companies with some money finding its way toward computing and ...
"It is imperative that healthcare providers educate their patients on how to administer the medication safely," experts told Newsweek.
Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, ...
“The cost of some diabetes medications has risen more than tenfold.” Eli Lilly and Company, Novo Nordisk and Sanofi, which ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on CureVac (CVAC – Research Report) today and set a price target of ...
Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) ...
Eli Lilly could potentially see $150 to $200 more in this stock ... The tech sector is in focus as leading AI company Nvidia (NVDA) prepares to report earnings on Wednesday. With expectations around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results